An Early Nabilone Review Reported Patient Preference Despite More Adverse Effects
A 1985 review described greater patient preference for nabilone than prochlorperazine in limited chemotherapy studies despite more side effects. Preference, symptom control and tolerability were related but distinct outcomes.
The comparison involved a specific clinical setting
The review focused on severe chemotherapy-associated gastrointestinal symptoms, including patients refractory to conventional therapy. Its conclusions concerned oral nabilone, a specified cannabinoid medicine. They cannot be transferred directly to smoked marijuana, retail CBD or every contemporary antiemetic regimen.
Preference did not mean fewer unwanted effects
The abstract described better symptom control and greater preference in limited comparisons while acknowledging a high incidence of drowsiness, dizziness and related symptoms. More troublesome effects could lead to discontinuation. A patient can prefer an intervention because of its benefit while still experiencing adverse effects; preference is not a stand-alone safety measure.
Missing comparators limited the treatment ranking
The authors identified additional comparator and combination trials that had not yet been undertaken. This means the review did not establish superiority over all possible treatments. Its 1985 assessment should remain historically bounded, rather than being presented as current prescribing guidance.
Interpreting the evidence
The useful reading separates efficacy, preference, adverse-event frequency and discontinuation. The review does not provide a basis for choosing or changing an individual patient's cancer-treatment regimen.
Related reading: selective cannabinoid-related findings in an animal withdrawal model.
Research reference
Ward A; Holmes B (1985). Nabilone. A preliminary review of its pharmacological properties and therapeutic use. Drugs. doi:10.2165/00003495-198530020-00002. Evidence basis: review abstract.
